Surveillance effective for childhood cancer predisposition syndrome management
Early detection of tumours in children with a cancer predisposition syndrome can be achieved with standardised surveillance protocols, US cohort study findings demonstrate.
Phoenix Sepsis Score ‘accurate’ for children undergoing cancer treatment
The Phoenix Sepsis Score “accurately” characterises the risk of definitely attributable mortality from sepsis and the duration of intensive care unit stay in children undergoing cancer treatment who have a suspected infection, US researchers report.
Pharmacogenomic-guided induction therapy might reduce pediatric AML racial disparities
Using a pharmacogenomic strategy to guide choice of induction therapy for acute myeloid leukaemia might help overcome the disparity in outcomes between Black and White children, suggests research published in JAMA Network Open.
Increasing measurable residual disease level predicts poorer AML outcomes
Research demonstrates a dose-dependent correlation between measurable residual disease and the likelihood of relapse and poor overall survival among adults with acute myeloid leukaemia who achieve complete remission before undergoing allogeneic haematopoietic cell transplantation.
Sepsis during paediatric leukaemia therapy linked to long-term neurocognitive dysfunction
Severe sepsis during treatment for childhood leukaemia may be associated with an increased risk of moderate-to-severe neurocognitive dysfunction in adulthood, US Study findings indicate.
EV-302 results ‘a leap forward’ for advanced urothelial carcinoma
Phase 3 trial findings demonstrate a significant improvement in overall survival for patients with treatment-naïve, advanced urothelial carcinoma who receive a combination of enfortumab vedotin and pembrolizumab compared with chemotherapy.
FOXO1 fusion status aids paediatric local rhabdomyosarcoma risk assessment
Considering FOXO1 fusion status improves the risk assessment of children with localised rhabdomyosarcoma, suggest study findings published in Cancer.
Tixagevimab plus cilgavimab offers COVID-19 protection for haematological cancer patients
Tixagevimab and cilgavimab immunoprophylaxis may help protect patients with haematological malignancies from COVID-19 infection and hospitalisation, suggests a research letter published in JAMA Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma
Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
